Roche paying $2.4B to acquire rest of US-based Foundation Medicine

Swiss drugmaker Roche’s $2.4 billion deal for U.S.-based Foundation Medicine represents an increased bet on gene-guided treatments to fight cancers. The agreement represents a a 29% premium over the June 18 value of Foundation Medicine’s shares.

     

 

 


Source: USA Today